- Home
- UL vs GILD Comparison
UL vs GILD Comparison
Compare UL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UL
- GILD
- Stock Information
- Founded
- UL 1930
- GILD 1987
- Country
- UL United Kingdom
- GILD United States
- Employees
- UL N/A
- GILD N/A
- Industry
- UL Package Goods/Cosmetics
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UL Consumer Discretionary
- GILD Health Care
- Exchange
- UL Nasdaq
- GILD Nasdaq
- Market Cap
- UL 151.6B
- GILD 138.2B
- IPO Year
- UL N/A
- GILD 1992
- Fundamental
- Price
- UL $59.55
- GILD $112.05
- Analyst Decision
- UL Strong Buy
- GILD Buy
- Analyst Count
- UL 4
- GILD 27
- Target Price
- UL $66.00
- GILD $105.32
- AVG Volume (30 Days)
- UL 2.5M
- GILD 10.5M
- Earning Date
- UL 04-08-2025
- GILD 04-24-2025
- Dividend Yield
- UL 3.15%
- GILD 2.82%
- EPS Growth
- UL N/A
- GILD N/A
- EPS
- UL 2.37
- GILD 0.38
- Revenue
- UL $62,906,097,959.00
- GILD $28,754,000,000.00
- Revenue This Year
- UL $5.65
- GILD $1.77
- Revenue Next Year
- UL $3.05
- GILD $3.52
- P/E Ratio
- UL $25.12
- GILD $294.87
- Revenue Growth
- UL 1.94
- GILD 6.04
- 52 Week Low
- UL $46.46
- GILD $62.07
- 52 Week High
- UL $65.87
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- UL 59.60
- GILD 58.06
- Support Level
- UL $57.67
- GILD $104.70
- Resistance Level
- UL $59.29
- GILD $107.42
- Average True Range (ATR)
- UL 0.53
- GILD 2.46
- MACD
- UL -0.02
- GILD -0.41
- Stochastic Oscillator
- UL 81.74
- GILD 68.25
About UL Unilever PLC
Unilever is a diversified personal-care (52% of 2022 sales by value), homecare (14%), and packaged food (34%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Axe and Dove skin products, and the TRESemmé haircare brand. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, Garancia, and The Vegetarian Butcher.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).